1
|
Jacques SK, McKeown J, Grover P, Johnson DB, Zaremba A, Dimitriou F, Weiser R, Farid M, Namikawa K, Sullivan RJ, Rutkowski P, Lebbe C, Hamid O, Zager JS, Michielin O, Neyns B, Nakamura Y, Robert C, Mehnert J, Ascierto PA, Bhave P, Park B, Zimmer L, Mangana J, Mooradian M, Placzke J, Allayous C, Glitza Oliva IC, Mehmi I, Depalo D, Wicky A, Schwarze JK, Roy S, Boatwright C, Vanella V, Long GV, Menzies AM, Lo SN, Carlino MS. Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy. Eur J Cancer 2024; 199:113563. [PMID: 38278007 DOI: 10.1016/j.ejca.2024.113563] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2023] [Revised: 01/02/2024] [Accepted: 01/17/2024] [Indexed: 01/28/2024]
Abstract
IMPORTANCE Acral (AM) and mucosal melanomas (MM) are rare subtypes with a poor prognosis. In those with advanced disease, anti-PD-1 (PD1) therapy has reduced activity compared to that seen in non-acral cutaneous melanoma. OBJECTIVE To determine the efficacy of adjuvant PD1 in resected AM or MM. DESIGN An international, retrospective cohort study SETTING: Data up to November 2021 collected from 20 centres across 10 countries. PARTICIPANTS One hundred and ninety four patients with resected stage III or IV1 AM or MM who received adjuvant PD1 were included and compared to matched patients from the Melanoma Institute Australia (MIA) database using a propensity score matching analysis. MAIN OUTCOMES AND MEASURES Recurrence-free survival (RFS), distant metastasis-free survival (DMFS) and overall survival (OS) were investigated. RESULTS Forty five of 139 (32%) AM and 9 of 55 (16%) MM patients completed adjuvant therapy. The main reason for early treatment cessation in both groups was disease recurrence: 51 (37%) and 30 (55%) in the AM and MM groups, respectively. In the AM group adjuvant PD1 was associated with a longer RFS [HR-0.69 (0.52-0.92, p = 0.0127)], DMFS [HR0.58 (0.38-0.89, p = 0.0134)] and OS [HR of 0.59 (0.38-0.92, p-value 0.0196)] when compared to the historical cohort. In the MM group there was no statistical difference in RFS [HR1.36 (0.69-2.68,p-value 0.3799], DMFS or OS. CONCLUSION AND RELEVANCE After adjuvant PD1, both AM and MM have a high risk of recurrence. Our data suggests a benefit to using adjuvant PD1 therapy in resected AM but not in resected MM. Additional studies to investigate the efficacy of adjuvant PD1 for MM are needed.
Collapse
Affiliation(s)
- Sarah K Jacques
- Department of Medical Oncology, Westmead and Blacktown Hospitals, Sydney, Australia
| | - Janet McKeown
- Melanoma Institute Australia, The University of Sydney, Sydney, Australia
| | - Piyush Grover
- Melanoma Institute Australia, The University of Sydney, Sydney, Australia
| | | | - Anne Zaremba
- Department of Dermatology, Venereology and Allergology, University Hospital Essen, Essen, Germany
| | - Florentia Dimitriou
- Department of Dermatology, University Hospital of Zurich and Faculty of Medicine, University of Zürich, Zurich, Switzerland
| | - Roi Weiser
- MD Anderson Cancer Center, Houston, TX, USA
| | | | - Kenjiro Namikawa
- Department of Dermatologic Oncology, National Cancer Center, Tokyo, Japan
| | - Ryan J Sullivan
- Massachusetts General Hospital, Harvard University, Boston, MA, USA
| | - Piotr Rutkowski
- Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
| | - Celeste Lebbe
- Université Paris Cite,AP-HP Dermato-oncology, Cancer institute APHP.nord Paris cité, INSERM U976, Saint Louis Hospital, Paris, France
| | - Omid Hamid
- The Angeles Clinic, A Cedars-Sinai Affiliate, Los Angeles, CA, USA
| | - Jonathan S Zager
- Department of Cutaneous Oncology, Moffit Cancer Center, Tampa, FL, USA
| | - Olivier Michielin
- Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland
| | - Bart Neyns
- Universitair Ziekenhuis Brussel, Brussels, Belgium
| | - Yasuhiro Nakamura
- Department of Skin Oncology/Dermatology, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Saitama, Japan
| | - Caroline Robert
- Institute Gustave Roussy and Paris Saclay University, Villejuif Cedex, France
| | | | - Paolo A Ascierto
- Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
| | - Prachi Bhave
- Sir Peter MacCallum Cancer Centre Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia
| | - Benjamin Park
- Vanderbilt University Medical Centre, Nashville, TN, USA
| | - Lisa Zimmer
- Department of Dermatology, Venereology and Allergology, University Hospital Essen, Essen, Germany
| | - Joanna Mangana
- Department of Dermatology, University Hospital of Zurich and Faculty of Medicine, University of Zürich, Zurich, Switzerland
| | - Megan Mooradian
- Massachusetts General Hospital, Harvard University, Boston, MA, USA
| | - Joanna Placzke
- Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
| | - Clare Allayous
- Université Paris Cite,AP-HP Dermato-oncology, Cancer institute APHP.nord Paris cité, INSERM U976, Saint Louis Hospital, Paris, France
| | | | - Inderjit Mehmi
- The Angeles Clinic, A Cedars-Sinai Affiliate, Los Angeles, CA, USA
| | - Danielle Depalo
- Department of Cutaneous Oncology, Moffit Cancer Center, Tampa, FL, USA
| | - Alexandre Wicky
- Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland
| | | | - Severine Roy
- Institute Gustave Roussy and Paris Saclay University, Villejuif Cedex, France
| | | | - Vito Vanella
- Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
| | - Georgina V Long
- Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Royal North Shore Hospital, Sydney, Australia
| | - Alexander M Menzies
- Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Royal North Shore Hospital, Sydney, Australia; Mater Hospital, Sydney, Australia
| | - Serigne N Lo
- Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia
| | - Matteo S Carlino
- Department of Medical Oncology, Westmead and Blacktown Hospitals, Sydney, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia.
| |
Collapse
|
2
|
Jacques S, McKeown J, Grover P, Park B, Zaremba A, Dimitriou F, Harunal Rashid M, Namikawa K, Mooradian M, Placzke J, Allayous C, Mehmi I, DePalo D, Wicky A, Schwarze J, Nakamura Y, Benannoune N, Menzies A, Lo S, Carlino M. 809P Outcomes of patients with resected stage III/IV acral or mucosal melanoma treated with adjuvant anti-PD-1 therapy. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.935] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
3
|
Dimitriou F, Namikawa K, Reijers ILM, Buchbinder EI, Soon JA, Zaremba A, Teterycz P, Mooradian MJ, Armstrong E, Nakamura Y, Vitale MG, Tran LE, Bai X, Allayous C, Provent-Roy S, Indini A, Bhave P, Farid M, Kähler KC, Mehmi I, Atkinson V, Klein O, Stonesifer CJ, Zaman F, Haydon A, Carvajal RD, Hamid O, Dummer R, Hauschild A, Carlino MS, Mandala M, Robert C, Lebbe C, Guo J, Johnson DB, Ascierto PA, Shoushtari AN, Sullivan RJ, Cybulska-Stopa B, Rutkowski P, Zimmer L, Sandhu S, Blank CU, Lo SN, Menzies AM, Long GV. Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. Ann Oncol 2022; 33:968-980. [PMID: 35716907 DOI: 10.1016/j.annonc.2022.06.004] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2022] [Revised: 05/15/2022] [Accepted: 06/07/2022] [Indexed: 11/01/2022] Open
Abstract
BACKGROUND Mucosal melanoma (MM) is a rare melanoma subtype with distinct biology and poor prognosis. Data on the efficacy of immune checkpoint inhibitors (ICIs) is limited. We determined the efficacy of ICIs in MM, analysed by primary site and ethnicity/race. PATIENTS AND METHODS Retrospective cohort study from 25 cancer centres in Australia, Europe, USA and Asia. Patients with histologically confirmed MM were treated with anti-PD1+/-ipilimumab. Primary endpoints were response rate (RR), progression-free survival (PFS), overall survival (OS) by primary site (naso-oral, urogenital, anorectal, other), ethnicity/race (Caucasian, Asian, Other) and treatment. Univariate and multivariate Cox proportional hazard model analyses were conducted. RESULTS In total, 545 patients were included: 331 (63%) Caucasian, 176 (33%) Asian and 20 (4%) Other. Primary sites included 113 (21%) anorectal, 178 (32%) urogenital, 206 (38%) naso-oral and 45 (8%) other. 348 (64%) received anti-PD1 and 197 (36%) anti-PD1/ipilimumab. RR, PFS and OS did not differ by primary site, ethnicity/race or treatment. RR for naso-oral was numerically higher for anti-PD1/ipilimumab (40%, 95% CI 29-54%) compared with anti-PD1 (29%, 95% CI 21-37%). 35% of patients that initially responded progressed. Median duration of response (mDOR) was 26 months (95% CI 18-NR [Not Reached]). Factors associated with short PFS were ECOG PS ≥3 (p<0.01), LDH >ULN (p=0.01), lung metastases (p<0.01) and ≥1 previous treatments (p<0.01). Factors associated with short OS were ECOG PS ≥1 (p<0.01), LDH >ULN (p=0.03), lung metastases (p<0.01) and ≥1 previous treatments (p<0.01). CONCLUSIONS MM has poor prognosis. Treatment efficacy of anti-PD1+/-ipilimumab was similar and did not differ by ethnicity/race. Naso-oral primaries had numerically higher response to anti-PD1/ipilimumab, without difference in survival. The addition of ipilimumab did not show greater benefit over anti-PD1 for other primary sites. In responders, mDOR was short and acquired resistance was common. Other factors, including site and number of metastases were associated with survival.
Collapse
Affiliation(s)
- F Dimitriou
- Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia; Department of Dermatology, University Hospital Zurich (USZ) and University of Zurich (UZH), Zurich, Switzerland; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
| | - K Namikawa
- Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - I L M Reijers
- Department of Medical Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - E I Buchbinder
- Melanoma Disease Center, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02481, USA
| | - J A Soon
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - A Zaremba
- Department of Dermatology, University Hospital Essen, Essen, Germany
| | - P Teterycz
- Department of Soft Tissue/Bone Sarcoma and Melanoma, 49585Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
| | - M J Mooradian
- Division of Oncology and Hematology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston MA, USA
| | - E Armstrong
- Department of Medicine, Melanoma Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Y Nakamura
- Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, Japan
| | - M G Vitale
- Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale', Napoli, Italy
| | - L E Tran
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - X Bai
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, Beijing, China
| | - C Allayous
- APHP Hôpital Saint-Louis, Dermatology Department, DMU ICARE, Paris, France
| | - S Provent-Roy
- Dermatology Service, Department of Medicine, Gustave Roussy and Paris-Saclay University, Villejuif, France
| | - A Indini
- Unit of Medical Oncology, Ospedale di Circolo e Fondazione Macchi, ASST Sette Laghi, Varese, Italy
| | - P Bhave
- Westmead and Blacktown Hospitals, Sydney, New South Wales, Australia
| | - M Farid
- Division of Medical Oncology, National Cancer Centre Singapore, 11 Hospital Crescent, Singapore, 169610, Singapore
| | - K C Kähler
- Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Germany
| | - I Mehmi
- Department of Hematology/Oncology, The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, 11800 Wilshire Blvd Suite 300, Los Angeles, CA, 90025, USA
| | - V Atkinson
- Princess Alexandra Hospital, Greenslopes Private Hospital, University of Queensland, Queensland, Australia
| | - O Klein
- Department of Medical Oncology, Austin Health, Melbourne, Australia; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria
| | - C J Stonesifer
- Columbia University Irving Medical Center, New York City, New York, USA
| | - F Zaman
- Alfred Hospital, Melbourne, Victoria, Australia
| | - A Haydon
- Alfred Hospital, Melbourne, Victoria, Australia
| | - R D Carvajal
- Columbia University Irving Medical Center, New York City, New York, USA
| | - O Hamid
- Department of Hematology/Oncology, The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, 11800 Wilshire Blvd Suite 300, Los Angeles, CA, 90025, USA
| | - R Dummer
- Department of Dermatology, University Hospital Zurich (USZ) and University of Zurich (UZH), Zurich, Switzerland
| | - A Hauschild
- Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Germany
| | - M S Carlino
- Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia; Westmead and Blacktown Hospitals, Sydney, New South Wales, Australia
| | - M Mandala
- Unit of Medical Oncology, University of Perugia, Perugia, Italy
| | - C Robert
- Dermatology Service, Department of Medicine, Gustave Roussy and Paris-Saclay University, Villejuif, France
| | - C Lebbe
- Université de Paris, APHP Hôpital Saint-Louis, Dermatology Department, DMU ICARE, INSERM U-976, Paris, France
| | - J Guo
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, Beijing, China
| | - D B Johnson
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - P A Ascierto
- Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale', Napoli, Italy
| | - A N Shoushtari
- Department of Medicine, Melanoma Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - R J Sullivan
- Division of Oncology and Hematology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston MA, USA
| | - B Cybulska-Stopa
- Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, Poland
| | - P Rutkowski
- Department of Soft Tissue/Bone Sarcoma and Melanoma, 49585Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
| | - L Zimmer
- Department of Dermatology, University Hospital Essen, Essen, Germany
| | - S Sandhu
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - C U Blank
- Department of Medical Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - S N Lo
- Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
| | - A M Menzies
- Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia
| | - G V Long
- Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia.
| |
Collapse
|
4
|
Yatim N, Boussier J, Tetu P, Smith N, Bruel T, Corneau A, Da Meda L, Allayous C, Grzelak L, Staropoli I, Hadjadj J, Le Goff J, Kramkimel N, Aractingi S, Blanc C, Rieux-Laucat F, Schwartz O, Terrier B, Duffy D, Lebbe C. Impact des inhibiteurs de checkpoints immunitaires au cours de la COVID-19 chez les patients atteints de mélanome. Rev Med Interne 2021. [PMCID: PMC8610730 DOI: 10.1016/j.revmed.2021.10.218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
5
|
Pires da Silva I, Zakria D, Ahmed T, Trojaniello C, Dimitriou F, Allayous C, Gerard C, Zimmer L, Lo S, Michielin O, Lebbe C, Mangana J, Ascierto P, Johnson D, Carlino M, Menzies A, Long G. 1042P Anti-PD1 (PD1) monotherapy or in combination with ipilimumab (IPI) after BRAF/MEK inhibitors (BRAF/MEKi) in BRAF mutant metastatic melanoma (MM) patients (pts). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
6
|
Owen CN, Bai X, Quah T, Lo SN, Allayous C, Callaghan S, Martínez-Vila C, Wallace R, Bhave P, Reijers ILM, Thompson N, Vanella V, Gerard CL, Aspeslagh S, Labianca A, Khattak A, Mandala M, Xu W, Neyns B, Michielin O, Blank CU, Welsh SJ, Haydon A, Sandhu S, Mangana J, McQuade JL, Ascierto PA, Zimmer L, Johnson DB, Arance A, Lorigan P, Lebbé C, Carlino MS, Sullivan RJ, Long GV, Menzies AM. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Ann Oncol 2021; 32:917-925. [PMID: 33798657 DOI: 10.1016/j.annonc.2021.03.204] [Citation(s) in RCA: 66] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2020] [Revised: 03/09/2021] [Accepted: 03/28/2021] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Immune-related adverse events (irAEs) typically occur within 4 months of starting anti-programmed cell death protein 1 (PD-1)-based therapy [anti-PD-1 ± anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4)], but delayed irAEs (onset >12 months after commencement) can also occur. This study describes the incidence, nature and management of delayed irAEs in patients receiving anti-PD-1-based immunotherapy. PATIENTS AND METHODS Patients with delayed irAEs from 20 centres were studied. The incidence of delayed irAEs was estimated as a proportion of melanoma patients treated with anti-PD-1-based therapy and surviving >1 year. Onset, clinical features, management and outcomes of irAEs were examined. RESULTS One hundred and eighteen patients developed a total of 140 delayed irAEs (20 after initial combination with anti-CTLA4), with an estimated incidence of 5.3% (95% confidence interval 4.0-6.9, 53/999 patients at sites with available data). The median onset of delayed irAE was 16 months (range 12-53 months). Eighty-seven patients (74%) were on anti-PD-1 at irAE onset, 15 patients (12%) were <3 months from the last dose and 16 patients (14%) were >3 months from the last dose of anti-PD-1. The most common delayed irAEs were colitis, rash and pneumonitis; 55 of all irAEs (39%) were ≥grade 3. Steroids were required in 80 patients (68%), as well as an additional immunosuppressive agent in 27 patients (23%). There were two irAE-related deaths: encephalitis with onset during anti-PD-1 and a multiple-organ irAE with onset 11 months after ceasing anti-PD-1. Early irAEs (<12 months) had also occurred in 69 patients (58%), affecting a different organ from the delayed irAE in 59 patients (86%). CONCLUSIONS Delayed irAEs occur in a small but relevant subset of patients. Delayed irAEs are often different from previous irAEs, may be high grade and can lead to death. They mostly occur in patients still receiving anti-PD-1. The risk of delayed irAE should be considered when deciding the duration of treatment in responding patients. However, patients who stop treatment may also rarely develop delayed irAE.
Collapse
Affiliation(s)
- C N Owen
- Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - X Bai
- Massachusetts General Hospital, Boston, USA; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma, Peking University Cancer Hospital & Institute, Beijing, China
| | - T Quah
- Westmead and Blacktown Hospitals, Sydney, Australia
| | - S N Lo
- Melanoma Institute Australia, The University of Sydney, Sydney, Australia
| | - C Allayous
- Dermatology Department, Université de Paris, AP-HP Saint-Louis Hospital, INSERM, Paris, France
| | - S Callaghan
- The Christie NHS Foundation Trust, Manchester, UK
| | | | - R Wallace
- Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, Australia
| | - P Bhave
- The Alfred Hospital, Melbourne, Australia
| | - I L M Reijers
- Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - N Thompson
- Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - V Vanella
- Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
| | - C L Gerard
- Lausanne University Hospital, Lausanne, Switzerland
| | - S Aspeslagh
- University Hospital Brussels, Brussels, Belgium
| | - A Labianca
- Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy
| | - A Khattak
- Fiona Stanley Hospital and Edith Cowan University, Perth, Australia
| | - M Mandala
- University of Perugia, Unit of Medical Oncology, Santa Maria misericordia hospital, Perugia, Italy
| | - W Xu
- Princess Alexandra Hospital and The University of Queensland, Brisbane, Australia
| | - B Neyns
- University Hospital Brussels, Brussels, Belgium
| | - O Michielin
- Lausanne University Hospital, Lausanne, Switzerland
| | - C U Blank
- Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - S J Welsh
- Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - A Haydon
- The Alfred Hospital, Melbourne, Australia
| | - S Sandhu
- Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, Australia
| | - J Mangana
- Dermatology, Department of Dermato-Oncology, University Hospital Zurich, Zürich, Switzerland
| | - J L McQuade
- The University of Texas MD Anderson Cancer Center, Houston, USA
| | - P A Ascierto
- Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
| | - L Zimmer
- Department of Dermatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - D B Johnson
- Vanderbilt University Medical Center, Nashville, USA
| | - A Arance
- Hospital Clinic Barcelona, Barcelona, Spain
| | - P Lorigan
- The Christie NHS Foundation Trust, Manchester, UK; The University of Manchester, Manchester, UK
| | - C Lebbé
- Dermatology Department, Université de Paris, AP-HP Saint-Louis Hospital, INSERM, Paris, France
| | - M S Carlino
- Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Westmead and Blacktown Hospitals, Sydney, Australia
| | | | - G V Long
- Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Royal North Shore Hospital, Sydney, Australia; Mater Hospital, Sydney, Australia.
| | - A M Menzies
- Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Royal North Shore Hospital, Sydney, Australia; Mater Hospital, Sydney, Australia
| |
Collapse
|
7
|
Tetu P, Sirven-Villaros L, Cuzzubbo S, Ursu R, Baroudjian B, Delyon J, Nataf F, De Margerie-Mellon C, Basset-Seguin N, Allayous C, Lefevre W, Carpentier A, Lebbé C. Impact des nouveaux traitements systémiques et de la radiothérapie cérébrale concomitante dans la prise en charge des patients présentant un mélanome avec atteinte leptoméningée. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
8
|
Tetu P, Baroudjian B, Delyon J, Basset-Seguin N, Allayous C, Oriano B, Lebbé C. Facteurs pronostiques et prédictifs associés au traitement par nivolumab et ipilimumab chez les patients présentant un mélanome métastatique. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
9
|
Di Filippo Y, Dalle S, Mortier L, Dutriaux C, Dalac S, Leccia MT, Legoupil D, Saiag P, Brunet-Possenti F, Arnault JP, Maubec E, Granel-Brocard F, De Quatrebarbes J, Aubin F, Lesimple T, Stoebner P, Dupuy A, Stephan AR, Grob JJ, Allayous C, Lefevre W, Dereure O, Lebbé C, Montaudié H. L’indice de masse corporelle est-il réellement prédictif des résultats des thérapies systémiques dans le mélanome métastatique ? Étude multicentrique de la cohorte française MelBase. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
10
|
Carlet C, Dalle S, Leccia MT, Mortier L, Dalac-Rat S, Dutriaux C, Legoupil D, Montaudie H, Dereure O, De Quatrebarbes J, Granel-Brocard F, Le Bouar M, Charles J, Brunet-Possenti F, Dreno B, Lefevre W, Allayous C, Lebbe C, Nardin C. Effets indésirables tardifs des anti-PD1 : étude nationale française multicentrique prospective (MELBASE). Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
11
|
Versluis J, Hendriks A, Weppler A, Brown L, de Joode K, Suijkerbuijk K, Zimmer L, Kapiteijn E, Allayous C, Johnson D, Hepner A, Mangana J, Bhave P, Jansen Y, Trojaniello C, Atkinson V, Storey L, de Vries E, Blank C, Jalving M. 1080MO The value of local therapy in treatment of solitary melanoma progression upon immune checkpoint inhibition. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1204] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
12
|
Del Regno L, Louveau B, Battistella M, Sadoux A, Baroudjian B, Delyon J, Serror K, Allayous C, Lebbe C, Mourah S, Jouenne F. Clinical significance of BRAF/NRAS concurrent mutations in a clinic-based metastatic melanoma cohort. Br J Dermatol 2019; 182:1281-1283. [PMID: 31675434 DOI: 10.1111/bjd.18641] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- L Del Regno
- Institute of Dermatology, Catholic University - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - B Louveau
- INSERM, UMR_S976, Paris, France.,Université de Paris, Paris, France.,Department of Pharmacogenomics, Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, 1 Avenue Claude Vellefaux, 75475, Paris cedex 10, France
| | - M Battistella
- INSERM, UMR_S976, Paris, France.,Université de Paris, Paris, France.,Department of Pathology, Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, 1 Avenue Claude Vellefaux, 75475, Paris cedex 10, France
| | - A Sadoux
- Department of Pharmacogenomics, Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, 1 Avenue Claude Vellefaux, 75475, Paris cedex 10, France
| | - B Baroudjian
- INSERM, UMR_S976, Paris, France.,Department of Dermatology, Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, 1 Avenue Claude Vellefaux, 75475, Paris cedex 10, France
| | - J Delyon
- INSERM, UMR_S976, Paris, France.,Université de Paris, Paris, France.,Department of Dermatology, Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, 1 Avenue Claude Vellefaux, 75475, Paris cedex 10, France
| | - K Serror
- General Surgery, Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, 1 Avenue Claude Vellefaux, 75475, Paris cedex 10, France
| | - C Allayous
- INSERM, UMR_S976, Paris, France.,Department of Dermatology, Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, 1 Avenue Claude Vellefaux, 75475, Paris cedex 10, France
| | - C Lebbe
- INSERM, UMR_S976, Paris, France.,Université de Paris, Paris, France.,Department of Dermatology, Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, 1 Avenue Claude Vellefaux, 75475, Paris cedex 10, France
| | - S Mourah
- INSERM, UMR_S976, Paris, France.,Université de Paris, Paris, France.,Department of Pharmacogenomics, Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, 1 Avenue Claude Vellefaux, 75475, Paris cedex 10, France
| | - F Jouenne
- INSERM, UMR_S976, Paris, France.,Université de Paris, Paris, France.,Department of Pharmacogenomics, Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, 1 Avenue Claude Vellefaux, 75475, Paris cedex 10, France
| |
Collapse
|
13
|
Colle E, Dalle S, Mortier L, Guillot B, Dutriaux C, Leccia MT, Dalac S, Legoupil D, Dequatrebarbes J, Montaudié H, Jean-Philippe A, Brunet-Possenti F, Saiag P, Vu LT, Momenzadeh M, Allayous C, Porcher R, Oriano B, Dréno B, Lebbé C. Hyperprogression sous traitement par anti-PD-1 pour les patients ayant un mélanome de stade III non résécable ou de stade IV métastatique. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
14
|
Dousset L, Boussemart L, Robert C, Mansard S, Lebbe C, Merlio JP, Routier E, Dupuy A, Rouanet J, Battistella M, Capellen D, Galibert MD, Allayous C, Lespagnol A, Villechenoux G, Gerard E, Kerneuzet I, Roy S, Vergier B, Beylot-Barry M. Tumour mutational burden and response to PD-1 inhibitors: An analysis of 89 cases of metastatic melanoma. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz255.043] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Kandel M, Allayous C, Dalle S, Mortier L, Dalac S, Dutriaux C, Leccia MT, Rotolo F, Guillot B, Saiag P, Lacour JP, Legoupil D, Lesimple T, Aubin F, Beylot-Barry M, Descamps V, Lok C, Granel-Brocard F, Stoebner PE, Dupuy A, Maubec E, Grob JJ, Dreno B, Ballon A, Michiels S, Lebbe C, Borget I. Réévaluation de la survie et du coût du mélanome métastatique : estimation à partir de la cohorte MELBASE. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
16
|
Mourad N, Delyon J, Lourenco N, Herms F, Allayous C, Ballon A, Allez M, Bertheau P, Madelaine I, Lebbé C, Baroudjian B. Toxicité digestive des MEK inhibiteurs au-delà des diarrhées banales. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
17
|
Tetu P, Allayous C, Oriano B, Dalle S, Mortier L, Leccia MT, Guillot B, Dalac S, Dutriaux C, Lacour JP, Saiag P, Descamps V, De Quatrebarbes J, Stoebner P, Legoupil D, Beylot-Barry M, Lesimple T, Aubin F, Dréno B, Mohamed S, Ballon A, Porcher R, Lebbé C. Impact de la radiothérapie cérébrale concomitante chez les patients présentant un mélanome avancé avec métastases cérébrales. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
18
|
Gauci ML, Baroudjian B, Bédérède U, Zéboulon C, Dupont A, Delyon J, Allayous C, Bagot M, Madelaine I, Resche-Rigon M, Poté N, Roux O, Bouattour M, Lebbé C. Hépatites aiguës induites par les immunothérapies anti-tumorales (HAII) : aspects cliniques et prise en charge. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
19
|
Huynh S, Baroudjian B, Allayous C, Ballon A, Herms F, Basset-Seguin N, Mourah S, Madelaine I, Lebbé C, Delyon J. Combinaison d’un anti-PD1 à une thérapie ciblant BRAF dans le traitement du mélanome métastatique : série de 9 cas. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
20
|
Kandel M, Allayous C, Dalle S, Mortier L, Dalac S, Dutriaux C, Leccia MT, Guillot B, Saiag P, Lacour JP, Legoupil D, Lesimple T, Aubin F, Beylot-Barry M, Brunet-Possenti F, Arnault JP, Granel-Brocard F, Stoebner PE, Dupuy A, Maubec E, Grob JJ, Dreno B, Rotolo F, Ballon A, Michiels S, Lebbe C, Borget I. Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort. Eur J Cancer 2018; 105:33-40. [PMID: 30384014 DOI: 10.1016/j.ejca.2018.09.026] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2018] [Revised: 08/16/2018] [Accepted: 09/24/2018] [Indexed: 01/07/2023]
Abstract
PURPOSE Since 2011, significant progress was observed in metastatic melanoma (MM), with the commercialisation of seven immunotherapies or targeted therapies, which showed significant improvement in survival. In France, in 2004, the cost of MM was estimated at €1634 per patient; this cost has not been re-estimated since. This study provided an update on survival and cost in real-life clinical practice. METHODS Clinical and economic data (treatments, hospitalisations, radiotherapy sessions, visits, imaging and biological exams) were extracted from the prospective MelBase cohort, collecting individual data in 955 patients in 26 hospitals, from diagnosis of metastatic disease until death. Survival was estimated by the Kaplan-Meier method. Costs were calculated from the health insurance perspective using French tariffs. For live patients, survival and costs were extrapolated using a multistate model, describing the 5-year course of the disease according to patient prognostic factors and number of treatment lines. RESULTS Since the availability of new drugs, the mean survival time of MM patients has increased to 23.6 months (95%confidence interval [CI] :21.2;26.6), with 58% of patients receiving a second line of treatment. Mean management costs increased to €269,682 (95%CI:244,196;304,916) per patient. Drugs accounted for 80% of the total cost. CONCLUSION This study is the first that evaluated the impact of immunotherapies and targeted therapies both on survival and cost in real-life conditions. Alongside the introduction of breakthrough therapies in the first and subsequent lines, MM has been associated with a significant increase in survival but also in costs, raising the question of financial sustainability.
Collapse
Affiliation(s)
- M Kandel
- Gustave Roussy, Service de Biostatistique et D'Epidémiologie, Villejuif, France; University Paris-Saclay, Univ. Paris-Sud, UVSQ, CESP, INSERM, Villejuif, France.
| | - C Allayous
- Dermatology and CIC, Assistance Publique des Hôpitaux de Paris, INSERM U976, University Paris Diderot-Saint-Louis Hospital, Paris, France
| | - S Dalle
- Dermatology, Hospices Civils de Lyon Hospital, Cancer Research Center of Lyon, Claude Bernard University, Lyon France
| | - L Mortier
- Dermatology, Lille Hospital, Lille, France
| | - S Dalac
- Dermatology, Dijon Hospital, Dijon, France
| | - C Dutriaux
- Dermatology, Bordeaux Saint-André Hospital, Bordeaux, France
| | - M T Leccia
- Dermatology, Grenoble Hospital, Grenoble, France
| | - B Guillot
- Dermatology, Montpellier Hospital, Montpellier, France
| | - P Saiag
- Dermatology, Assistance Publique des Hôpitaux de Paris, Ambroise Paré Hospital, Boulogne-Billancourt, France
| | - J P Lacour
- Dermatology, Nice Hospital, Nice, France
| | - D Legoupil
- Dermatology, Brest Hospital, Brest, France
| | | | - F Aubin
- Dermatology, Besançon Hospital, Besançon, France
| | - M Beylot-Barry
- Dermatology, Bordeaux Haut-L'évêque Hospital, Bordeaux, France
| | - F Brunet-Possenti
- Dermatology, Assistance Publique des Hôpitaux de Paris, Bichat Hospital, Paris, France
| | - J P Arnault
- Dermatology, Amiens Hospital, Amiens, France
| | | | | | - A Dupuy
- Dermatology, Rennes Hospital, Rennes, France
| | - E Maubec
- Dermatology, Assistance Publique des Hôpitaux de Paris, Avicennes Hospital, University Paris 13, France
| | - J J Grob
- Dermatology, La Timone Hospital, Marseille, France
| | - B Dreno
- Dermatology, Nantes Hospital, Nantes, France
| | - F Rotolo
- Gustave Roussy, Service de Biostatistique et D'Epidémiologie, Villejuif, France; University Paris-Saclay, Univ. Paris-Sud, UVSQ, CESP, INSERM, Villejuif, France
| | - A Ballon
- Dermatology and CIC, Assistance Publique des Hôpitaux de Paris, INSERM U976, University Paris Diderot-Saint-Louis Hospital, Paris, France
| | - S Michiels
- Gustave Roussy, Service de Biostatistique et D'Epidémiologie, Villejuif, France; University Paris-Saclay, Univ. Paris-Sud, UVSQ, CESP, INSERM, Villejuif, France
| | - C Lebbe
- Dermatology and CIC, Assistance Publique des Hôpitaux de Paris, INSERM U976, University Paris Diderot-Saint-Louis Hospital, Paris, France
| | - I Borget
- Gustave Roussy, Service de Biostatistique et D'Epidémiologie, Villejuif, France; University Paris-Saclay, Univ. Paris-Sud, UVSQ, CESP, INSERM, Villejuif, France; GRADES, University Paris-Sud, France
| |
Collapse
|
21
|
Allayous C, Oriano B, Dalle S, Mortier L, Leccia MT, Guillot B, Jeudy G, Dutriaux C, Lacour JP, Saiag P, Brunet-Possenti F, De Quatrebarbes J, Stoebner PE, Legoupil D, Beylot-Barry M, Lesimple T, Aubin F, Ballon A, Porcher R, Lebbe C. Concomitant radiotherapy in melanoma brain metastases using the propensity score matching within the French cohort, MelBase. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy289.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Kandel M, Allayous C, Dalle S, Mortier L, Dalac Rat S, Dutriaux C, Leccia MT, Guillot B, Saiag P, Lacour JP, Legoupil D, Brunet-Possenti F, Dreno B, Ballon A, Bardet A, Michiels S, Lebbe C, Borget I. Assessment of quality of life in patients with metastatic melanoma in real clinical practice in France. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy289.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
23
|
Allayous C, Dalle S, Leccia MT, Dutriaux C, Mortier L, Guillot B, Dalac S, Lacour JP, Stoebner PE, Saiag P, Beylot-Barry M, Descamps V, Maubec E, de Quatrebarbes J, Lesimple T, Aubin F, Dupuy A, Ballon A, Oriano B, Lebbe C. Traitement en vie réelle des métastases cérébrales par thérapie ciblée : expérience de la cohorte française MelBase. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
24
|
Allayous C, Dalle S, Mortier L, Leccia MT, Aubin F, Dalac S, Guillot B, Lacour JP, Legoupil D, Saiag P, Dutriaux C, Descamps V, Maubec E, de Quatrebarbes J, Lesimple T, Arnault JP, Porcher R, Ballon A, Oriano B, Lebbe C. Effet du délai de switch dans une stratégie séquentielle d’immunothérapie sur l’efficacité de l’immunothérapie : expérience de la cohorte MelBase. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
25
|
Allayous C, Dalle S, Leccia MT, Dalac S, Guillot B, Legoupil D, Lacour JP, Dutriaux C, Saiag P, Aubin F, Descamps V, Beylot-Barry M, Arnault JP, de Quatrebarbes J, Lesimple T, Maubec E, Ballon A, Oriano B, Mortier L, Lebbe C. Données actualisées d’efficacité et de tolérance des anti-PD1 en vie réelle chez 398 patients au travers de la cohorte MelBase. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
26
|
Allayous C, Dalle S, Mortier L, Leccia MT, Dalac S, Aubin F, Dutriaux C, Beylot-Barry M, Lacour JP, Saiag P, Lesimple T, Granel-Brocard F, Maubec E, Descamps V, Arnault JP, Guillot B, De Quatrebarbes J, Stoebner PE, Dupuy A, Stephan A, Dreno B, Mohamed S, Kowal A, Porcher R, Borget I, Lebbe C. Données actualisées d’efficacité et de tolérance de l’ipilimumab en « vie réelle » via la cohorte Melbase. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.243] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
27
|
Dalle S, Lacour JP, Mortier L, Dutriaux C, Saiag P, Dalac S, Aubin F, Maubec E, Descamps V, Beylot-Barry M, Lesimple T, Arnault JP, De Quatrebarbes J, Stoebner PE, Guillot B, Legoupil D, Dreno B, Chami I, Porcher R, Kowal A, Allayous C, Leccia MT, Lebbe C. Traitement des métastases cérébrales par les inhibiteurs du checkpoint immunitaire : expérience de la cohorte nationale MelBase. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
28
|
Vallet A, Dalle S, Mortier L, Leccia MT, Dalac S, Dutriaux C, Saiag P, Guillot B, Lacour JP, Beylot-Barry M, Lok C, Legoupil D, Aubin F, Lesimple T, De Quatrebarbes J, Maubec E, Descamps V, Dreno B, Granel-Brocard F, Stoebner PE, Dupuy A, Porcher R, Kowal A, Allayous C, Lebbé C. Existe-t-il un lien entre le temps de dormance de la maladie micrométastatique et la survie du mélanome à un stade avancé ? Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
29
|
Hefez L, Dalle S, Dalac S, Beylot-Barry M, Leccia MT, Mortier L, Lacour JP, Dutriaux C, Saiag P, Dreno B, Guillot B, Lesimple T, Arnault JP, Porcher R, Kowal A, Allayous C, Lebbé C. Caractérisation des progressions secondaires sous anti-PD1 : étude non interventionnelle basée sur l’expérience de la cohorte MelBase. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
30
|
Dalle S, Mortier L, Dutriaux C, Dalac S, Leccia M, Saiag P, Dreno B, Kowal A, Allayous C, Lebbe C. 502 MelBase, a French national cohort dedicated to melanoma unresectable stage III and IV patients. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.06.524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
31
|
Allayous C, Dalle S, Leccia MT, Dutriaux C, Stoebner PE, Dalac S, Aubin F, Saiag P, Lacour JP, Lesimple T, Dupuy A, Mortier L, Beylot-Barry M, Maubec E, Arnault JP, Stephan A, Dreno B, Kowal A, Porcher R, Lebbe C. Efficacité et tolérance du vemurafenib chez des patients atteints de mélanome avancé muté BRAF V600 : expérience de la cohorte nationale MelBase. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
32
|
Allayous C, Leccia MT, Saiag P, Mortier L, Lacour JP, Dalac S, Lesimple T, Granel-Brocard F, Beylot-Barry M, Maubec E, Aubin F, Arnault JP, Dutriaux C, Dupuy A, Stephan A, Stoebner PE, Dreno B, Porcher R, Kowal A, Dalle S, Lebbe C. Premières données nationales en vie réelle de patients traités par ipilimumab et suivis dans la cohorte multicentrique MelBase. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
33
|
Chami I, Goldwirt L, Feugeas J, Pagès C, Brunet-Possenti F, Basset-Seguin N, Allayous C, Baroudjian B, Madelaine I, Roux J, Sauvageon H, Mourah S, Lebbé C. Dosage plasmatique de vémurafénib et valeur prédictive thérapeutique. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
34
|
Vatel A, Baroudjian B, Pagès C, Battistella M, Basset-Seguin N, Allayous C, Viguier M, Madjlessi-Ezra N, Bagot M, Mourah S, Lebbé C. Réponse aux anti-PD-1 dans le mélanome muqueux à un stade avancé. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.499] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
35
|
Allayous C, Leccia MT, Dalle S, Mortier L, Dalac S, Dutriaux C, Saiag P, Lacour JP, Lesimple T, Stoebner PE, Beylot-Barry M, Maubec E, De Quatrebarbes J, Aubin F, Arnault JP, Dreno B, Porcher R, Kowal A, Lebbé C. Première étude multicentrique française de l’efficacité et de la toxicité du dabrafénib en vie réelle dans le mélanome avancé muté BRAF V600 : analyse de la cohorte MelBase. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
36
|
Goldwirt L, Chami I, Feugeas JP, Pages C, Brunet-Possenti F, Allayous C, Baroudjian B, Madelaine I, Sauvageon H, Mourah S, Lebbé C. Reply to 'Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance' by Funck-Brentano et al. Ann Oncol 2015; 27:363-4. [PMID: 26578723 DOI: 10.1093/annonc/mdv538] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- L Goldwirt
- Department of Pharmacology, AP-HP, Saint-Louis Hospital, Inserm, U976 Université Paris Diderot, Sorbonne Paris Cité, UMR-S-976, Paris
| | - I Chami
- Department of Dermatology, AP-HP, Saint-Louis Hospital, Paris Inserm, U 976, Paris Faculté de Médecine, Université Paris Diderot, Sorbonne Paris Cité, Paris
| | - J-P Feugeas
- INSERM, IAME, UMR 1137, Université Paris Diderot, Paris
| | - C Pages
- Department of Dermatology, AP-HP, Saint-Louis Hospital, Paris Inserm, U 976, Paris Faculté de Médecine, Université Paris Diderot, Sorbonne Paris Cité, Paris
| | - F Brunet-Possenti
- Department of Dermatology, AP-HP, Saint-Louis Hospital, Paris Inserm, U 976, Paris Faculté de Médecine, Université Paris Diderot, Sorbonne Paris Cité, Paris
| | - C Allayous
- Department of Dermatology, AP-HP, Saint-Louis Hospital, Paris Inserm, U 976, Paris Faculté de Médecine, Université Paris Diderot, Sorbonne Paris Cité, Paris
| | - B Baroudjian
- Department of Dermatology, AP-HP, Saint-Louis Hospital, Paris Inserm, U 976, Paris Faculté de Médecine, Université Paris Diderot, Sorbonne Paris Cité, Paris
| | - I Madelaine
- Deparment of Pharmacy, AP-HP, Saint-Louis Hospital, Paris, France
| | - H Sauvageon
- Department of Pharmacology, AP-HP, Saint-Louis Hospital, Inserm, U976 Université Paris Diderot, Sorbonne Paris Cité, UMR-S-976, Paris
| | - S Mourah
- Department of Pharmacology, AP-HP, Saint-Louis Hospital, Inserm, U976 Université Paris Diderot, Sorbonne Paris Cité, UMR-S-976, Paris
| | - C Lebbé
- Department of Dermatology, AP-HP, Saint-Louis Hospital, Paris Inserm, U 976, Paris Faculté de Médecine, Université Paris Diderot, Sorbonne Paris Cité, Paris
| |
Collapse
|